Diagnosis and supportive therapeutic management of cardiac light chain amyloidosis—a cardiologist’s perspective

Summary Cardiac amyloidosis is caused by deposition of abnormally folded proteins (amyloid). The most common forms which present with cardiac involvement are light-chain (AL) and transthyretin (ATTR). Even novel treatments emerging, the prognosis these patients remains poor once amyloid deposits in heart. Therefore, knowledge on clinical imaging features crucial to make an early diagnosis improve patient outcomes. This article reviews important diagnostic findings gives overview therapeutic management patients, including supportive-, device- disease-specific drug therapies focusing AL amyloidosis.